WO1999055895A1

WO1999055895A1 - A new glucose-6-phosphate translocase inhibitor l 970871 from an actinomycete sp., and chemical derivatives thereof, a process for the preparation and their use as pharmaceuticals

Info

Publication number: WO1999055895A1
Application number: PCT/EP1999/002670
Authority: WO
Inventors: Nirogi Venkata Satya Ramakrishna; Erra Koteswara Satya Vijaya Kumar; Keshavapura Hosamane Sreedhara Swamy; Rajan Mukund Panshikar; Jayant Hanumanthrao Patil; Bhavna Ramesh Jotwani; Hemant Chaubal; Mythili Raman
Original assignee: Aventis Pharma Deutschland Gmbh
Priority date: 1998-04-27
Filing date: 1999-04-21
Publication date: 1999-11-04
Also published as: AU3709599A

Abstract

The present invention relates to a novel glucose-6-phosphate translocase inhibitor L 970871, which is produced by an Actinomycete sp. (culture number HIL-007997) during fermentation, a process for its preparation, to chemical derivatives derived from compound L 970871, to the use of compound L 970871 and derivatives derived therefrom and pharmacological active substances, as medicament and, in particular, for the treatment of diabetes mellitus, and to an Actinomycete sp. HIL-007997(DSM 11993) for producing the abovementioned compound L 970871.

Description

A new glucose-6-phosphate translocase inhibitor L 970871 from an Actinomycete sp., and chemical derivatives thereof, a process for the preparation and their use as pharmaceuticals

This invention relates to a new compound L 970871 obtainable from an Actinomycete sp. (culture number Y-94,007, HIL-007997), a process for their peparation, and their use in the manufacture of medicaments.

Increased rate of hepatic glucose output is a general feature of diabetes mellitus. In particular, there is a strong correlation between fasting plasma glucose level in non- insulin dependent diabetes mellitus (NIDDM) and hepatic glucose output. The two pathways by which glucose is produced in the liver are gluconeogenesis and glycogenolysis. The terminal steps of both pathways is catalysed by the microsomal glucose-6-phosphatase, a key enzyme in the homeostatic regulation of blood glucose levels. The level of this enzyme has also been known to be elevated in both experimental and pathological conditions of diabetes. Interference with this enzyme system should, therefore, result in a reduced hepatic glucose production.

Hepatic glucose-6-phosphatase is a multicomponent system comprised of atleast three functional activities: a glucose-6-phosphate translocase (T1 ), a glucose-6-phosphate phosphohydrolase and a phosphate/pyrophosphate translocase (T2). The glucose-6- phosphate translocase facilitates transport of glucose-6-phosphate into the lumen of the endoplasmic reticulum (ER). The phoshohydrolase, with its active site situated on the lumenal surface of the ER, hydrolyses glucose-6-phosphate and releases glucose and phosphate into the lumen. While the efflux of phosphate is facilitated by the phosphate/pyrophosphate translocase, the exact mechanism of glucose efflux is still not clear.

The high degree of substrate specificity of glucose-6-phosphate translocase makes this a potential target for pharmacological intervention in the treatment of diabetes mellitus. Thus, amongst physiologically occurring sugar phosphates, only glucose-6-phosphate 2 is transported by the translocase. In contrast, the phosphatase is non-specific and is known to hydrolyse a variety of organic phosphate esters.

A series of non-specific inhibitors of glucose-6-phosphatase has been described in the literature, e.g. phlorrhizin [J. Biol. Chem., 242, 1955-1960 (1967)], 5,5'-dithio-bis-2- nitrobenzoic acid [Biochem. Biophys. Res. Commun., 48, 694-699 (1972)], 2,2'- diisothiocyanatostilbene and 2-isothiocyanato-2'-acetoxystilbene [J. Biol. Chem., 255, 1113-1119 (1980)]. The first therapeutically utilizable inhibitors of the glucose-6- phosphatase system are proposed in European Patent Nos. 0587087 (Application No. 93114260.8) and 0587088 (Application No. 93114261.6). Kodaistatin A [Indian Patent Application No. 69/BOM/97 dt. Feb. 4, 1997; EP Appl. No. 97106453.0 dt. April 18, 1997] and Kodaistatins B-D [Indian Patent Application No. 562/BOM/97 dt. Sept. 26, 1997] are the first glucose-6-phosphate translocase inhibitors from microbial sources.

According to one object of the invention, there is provided a compound with the molecular formular C₂₈H₁₆O₁₁ (L 970871 ) obtainable from from an Actinomycete sp (culture number HlL-007997). L 970871 may be described as a glucose-6- phosphate translocase inhibitor.

L 970871 has a hitherto unreported new structure belonging to anthraquinone class of compounds. A chemical abstract literature search using search keys of the molecular formula established L 970871 to be a new compound. No other compound represented the structural features of L 970871.

The microorganism, culture number HIL-007997 used for the production of L 970871 was isolated from a soil sample collected from Rahne National Park, Mumbai, India. The microorganism HIL-007997 belongs to the order of Actinomycetales and has been deposited with the German Collection of Microorganisms and Cell Cultures, Braunschweig, Germany with an accession number DSM No. 11993.

Therefore, another object of the present invention is to provide a process for the production of a new compound named L 970871 from culture number HIL-007997, 3 its mutants and variants. The said process comprises cultivation of culture HIL- 007997, its mutants and variants, under aerobic conditions in a nutrient medium containing sources of carbon and nitrogen, nutrient inorganic salts followed by isolation and purification of the said compound from the culture filtrate.

Further aspects of the invention include: pharmaceutical compositions containing the compound L 970871 or chemical derivatives thereof together with a pharmaceutically tolerated auxiliary and/or excipient, the use of the compound L 970871 or chemical derivatives thereof for the manufacture of a medicament for the treatment and/or prophylaxis of diabetes mellitus and the Actinomycete sp. culture number HIL-007997 (DSM 11993) and ist mutants and/or variants.

The nutrient medium contains sources of carbon, nitrogen and inorganic salts. The carbon sources are, for example, starch, glucose, surcose, dextrin, fructose, molasses, glycerol, lactose or galactose, preferably glucose. The sources of nitrogen are soyabean meal, peanut meal, yeast extract, beef extract, peptone, tryptone, malt extract, corn steep liquor, gelatin or casamino acids, preferably soyabean meal and corn steep liquor. The nutrient inorganic salts are sodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, calcium chloride, calcium carbonate, potassium nitrate, ammonium sulphate or magnesium sulphate, preferably cobalt chloride and calcium carbonate.

Cultivation of culture No. HIL-007997 may be carried out at temperatures between 25-30°C and pH between 6.0 and 8.0. Preferably culture No. HIL-007997 is cultivated at 27°C (+ 1 °C) and pH 7.0.

The fermentation is preferably carried out for 40 to 70 hours when an optimal yield of L 970871 of the present invention is obtained. It is particularly preferred to carry out the fermentation for 60-70 hours under submerged conditions in shake flasks and 43-48 hours in laboratory fermenters. If desired, Desmophen^® (Polypropylene oxide) may be used as an antifoam agent in the fermenters. The progress of fermentation and formation of L 970871 can be detected by measuring the inhibition 4 of glucose-6-phospate activity in untreated and triton X-100^® disrupted rat liver microsomes in microtitre plates at room temperature using a colorimetric assay as described in Methods in Enzymology, 174, 58-67 (1989) with some modifications. In the resulting culture broth, L 970871 is present only in the culture filtrate. Thus, it can be recovered by extraction of the culture filtrate with a water immiscible solvent such as ethyl acetate, dichloromethane, chloroform or butanol at pH 5-8 or by hydrophobic interaction chromatography using polymeric resins such as "Diaion HP- 20^®" (Mitsubishi Chemical Industries Limited, Japan), "Amberiite XAD^® (Rohm and Hass Industries U.S.A.) activated charcoal or ion exchange chromatography at pH 5-8. The preferred method is adsorption over "Diaion HP-20" followed by desorption of the compound using eluants such as water, methanol, acetone or acetonitrile or combinations thereof. Concentration and lyophilization of the active eluates gives the crude compound.

The crude material can be further purified by using any of the following techniques: normal phase chromatography (using alumina or silica gel as stationary phase and eluents such as ethyl acetate, chloroform, methanol or combinations thereof), reverse phase chromatography (using reverse phase silica gel like dimethyl- octadecylsilylsilica gel, also called RP-18 or dimethyloctylsilylsilica gel also called RP-8 as stationary phase and eluents such as water, buffers viz. phosphate, acetate, citrate (pH 2-8) and organic solvents such as methanol, acetonitrile or acetone, or combinations of these solvents), gel permeation chromatography using resins such as "Sephadex LH-20^®" (Pharmacia Chemical Industries, Sweden), TSKgel Toyopearl HW-40F (TosoHaas, Tosoh Corporation, Japan) in solvents such as methanol, chloroform or ethyl acetate or their combinations or Sephadex G- 10 and G-25 in water; or by counter-current chromatography using a biphasic eluent system made up of two or more solvents such as water and chloroform. These techniques may be used repeatedly or a combination of the different techniques may be used. The preferred method is chromatography over Toyopearl followed by reverse phase modified silica gel (RP-18). 5

L 970871 can be administered orally, intramuscularly or intravenously. Pharmaceuticals which contain L 970871 or in combinations as the active substance is subject of the present invention also. They can be prepared by mixing the active compound with one or more pharmacologically tolerated auxiliaries and/or excipients such as, for example, fillers, emulsifiers, lubricants, masking flavours, colorants or buffer substances, and converted into a suitable pharmaceutical form such as, for example, tablets, coated tablets, capsules, granules, powders, emulsions, suspensions or solutions suitable for parenteral administration.

Examples of auxiliaries and/or excipients which may be mentioned are tragacanth, lactose, talc, agar-agar, polyglycols, ethanol and water. Suitable and preferred for parenteral administration are suspension or solutions in water. It is also possible to administer the active substances as such, without vehicles or diluents, in a suitable form, for example, in capsules.

The dosage of the active compound L 970871 to be administered and the frequency of administration depend on the potency of the active compound and additionally on the nature and severity of the disease to be treated and on the sex, age, weight and individual responsiveness of the mammal to be treated. On an average, the daily dose of the compound L 970871 in a human patient of about 75 kg weight is at least 1 mg to at most 500 mg, preferably from about 10 mg to 250 mg, it being possible, according to requirement, in several doses per day, and also, where appropriate, to be lower or higher.

The compound L 970871 may be converted into its pharmaceutically acceptable salts and derivatives like esters and ethers. Salts like sodium may be prepared by treating the active compound L 970871 with the corresponding bases. Esters may be prepared by reacting the compound L 970871 with carboxylic acids in the presence of a catalystor by treating the compound with acylating agents such as acid chlorides. Other methods of preparation of esters are given in literature [Advanced Organic Synthesis, 4th Edition, J. March, John Wiley & Sons, 1992]. 6

Ethers may be prepared from L 970871 by reaction with alkylating agents under basic conditions. Other methods of preparation of ethers are given [Advanced Organic Synthesis, 4th Edition, J. March, John Wiley & Sons, 1992].

The following examples are illustrative of the present invention but not limitative of the scope thereof :

Example 1

Isolation of the culture HIL-007997 from soil

(a) Composition of nutrient isolation medium:

Corn starch: 10.0 g

Casein: 1.0 g

Peptone: 1.0 g

Yeast extract: 1.0 g

K₂HPO₄: 0.5 g

Agar powder: 13.0 g

Demineralized water: 1.0 litre

PH: 7.5

(b) Soil plating and isolation:

10 g of soil collected from National Park, Mumbai, Maharahtra, India was added to 90 ml of sterilized demineralized water in 250 ml Erlenmeyer flask which was then shaken for 2 hours on a rotary shaker (220 rpm). The above soil suspension was then serially diluted in steps of 10 upto 10^"5. From the last dilution, 1 ml of suspension was placed at the centre of a sterile glass petri plate (15 cms diameter) in which was then poured approximately 50 ml of the above isolation medium supplemented with 75 μg/ml of cycloheximide, 5 μg/ml of ampicillin and 25 μg/ml of framycetin. The medium was cooled to 45°C before pouring and the plate swirled thoroughly. The mixture of soil suspension and medium was allowed to settle and incubated at 30°C (+ 1°C) for 7 days. The petri plate was periodically observed and the culture No. HIL-007997 was isolated from amongst the growing microorganisms. 7

Example 2

Maintenance of the culture HIL-007997

Culture No. HIL-007997 was maintained on the following medium :

Malt extract: 10.0 g

Yeast extract: 4.0 g

Glucose: 4.0 g

Agar powder: 13.0 g

Demineralized water: 1.0 litre

pH: 7.0

After dissolving the above mentioned ingredients throughly by heating, it was distributed in test tubes and then sterilized at 121 °C for 20 minutes. The test tubes were then cooled and allowed to solidify in a slanting position. The agar slants were streaked with the growth of the culture No. HIL-007997 by a wire loop and incubated at 28°C (+ 1 °C) until a good growth was observed. The well grown cultures were stored in the refrigerator at 8°C.

Example 3

Fermentation of culture HIL-007997 in shake flasks

Composition of seed medium :

Glucose: 15.0 g

Soyabean meal: 15.0 g

Com steep liquor: 5.0 g

NaCI: 5.0 g

CaCO₃: 2.0 g

Demineralized water: 1.0 litre

pH: 7.0 8

The above seed medium was distributed in 80 ml amounts in 500 ml Erienmeyer flasks and autoclaved at 121 ° C for 20 minutes. The flasks were cooled to room temperature and each flask was then inoculated with a loopful of the above mentioned well grown culture of Example 2 and shaken on a rotary shaker for 72 hours at 240 rpm at 27°C (+ 1 °C) to give seed culture.

Composition of the production medium

Glucose: 20.0 g

Soyabean meal: 10.0 g

CaCO₃: 0.2 g

Cobalt chloride: 0.001 g

Demineralized water: 1.0 litre

pH: 7.0

The production medium was distributed in 60 ml amounts in 500 ml Erienmeyer flasks and autoclaved at 121 °C for 20 minutes. The flasks were cooled to room temperature and then inoculated with the above mentioned seed culture (1 % v/v). The fermentation was carried out on a rotary shaker at 240 rpm and at a temperature of 27°C (+ 1°C) for 66 hours.

The production of L 970871 was monitored by measuring the inhibition of glucose-6- phosphate translocase. After harvesting, the culture broth was centhfuged and L 970871 was isolated from the culture filtrate and purified as described in Example 5.

Example 4

Fermentation of the culture No. HIL-007997 in fermenters

Stage 1 : Preparation of seed culture in shake flasks

The seed medium of Example 3 was distributed in 160 ml amounts in 1 L Erienmeyer flasks and autoclaved for 20 minutes. The seed culture was grown in these flasks as described in Example 3. 9

Stage 2 : Preparation of seed culture in fermenter

20 litres of the seed medium, as described in Example 3, in a 30 litre Marubishi fermenter was sterilized in situ for 45 minutes at 121 °C, cooled to 27° + 1 °C and seeded with 1.4 litres of the seed culture mentioned above.

The fermentation was run with the following parameters :

Temperature 27°C ( _L0.5°C) Agitation 100 rpm

Aeration 20 1 pm Harvest time 24 hrs.

Stage 3 : Large scale fermentation

250 litres of the production medium, as described in Example 3, in a 390 litre fermenter along with 50 ml of desmophen^® (Polypropylene oxide) as antifoam agent was sterilized in situ for 45 minutes at 121 °C, cooled to 27° + 1 °C and seeded with 20 litres of the seed culture from Stage 2.

The fermentation was run with the following parameters

Temperature 27°C (+ 0.5°C) Agitation 100 rpm Aeration 120 1 pm Harvest time 45 hrs.

The production of the compound was monitored by measuring the inhibition of glucose-6-phosphate translocase. When fermentation was discontinued, the pH of the culture broth was 6.0-7.0. The culture broth was centrifuged after harvesting and the glucose-6-phosphate translocase inhibitor L 970871 was isolated from the culture filtrate as described below in Example 5. 10 WO 99/55895 PCT/EP99/02670

Example 5:

Isolation and Purification of L 970871

Approximately 300 litres of culture broth was harvested and separated from the mycelium by centrifugation. L970871 was found to be present in culture filtrate. The culture filtrate (215 litres) was passed through a column of Diaion HP-20 (6.5 litres, 3 % v/v). The column was thorougly washed with demineralized water (15 litres) and t50% methanol (25 litres). The fractions were collected in 5 litres size. The active eluates (3 x 5 litres), obtained with 50% methanol were combined, concentrated under reduced pressure of 10-100 mm of Hg at 35 °C and lyophillized to yield the crude active material (69 g) showing an IC₅o θf 28 μg/ml.

The crude material was passed through a second Diaion HP-20 column (1.4 litres). The column was thorougly washed with demineralized water (5 litres) and then eluted with a step gradient of methanol in water. The fractions were collected in 500 ml size. The active eluates, obtained in 75% methanol in water, were combined, concentrated under reduced pressure of 10-100mm of Hg at 35 °C and lyophillized to obtain enriched material (3.61 g) having an IC₅₀ of 9 μg/ml.

The above enriched material was purified by passing through Sephadex LH-20 (350 ml) packed in a glass column. The mobile phase was methanol and the flow rate was maintained at 1.0 ml/min. The fractions were collected in 15 ml. size. The active fractions were pooled, concentrated under reduced pressure of 10-100mm of Hg at 35 °C and lyophillized to get semi-pure L 970871 (205 mg) having an IC₅o of 1.1 μg/ml. The semi-pure material thus obtained, was further purified by reverse phase preparative HPLC using Merck Hibar (Lichrosphere) RP-18e, 10 μM, (250 mm x 25 mm) column. The mobile phase was 100% water to 100% methanol in 40 min. at a flow rate of 10 ml/min and UV detection at 280 nm. 29 mg of pure compound L 970871 having an IC₅o of 0.82 μg/ml was obtained.

The purity of the compound L 970871 was checked by HPLC (High Pressure Liquid Chromatography) on a LiChrocart (250 mm x 4 mm) RP Select B (5μ) column using 11 a gradient of 0.1 % aqueous orthophospharic acid (pH 2.5) to CH₃CN in 20 min at a flow rate of 1 ml/min and UV detection at 280 nm.

L 970871 inhibits potently the activity of rat liver microsomal glucose-6-phosphate translocase with an IC₅o of about 1.6 μM. In contrast, L 970871 inhibits phosphatase activity in detergent-disrupted microsomes with an IC₅₀ of about > 100 μM indicating a high degree of specificity for translocase. Further, L 970871 did not affect the activity of phosphate/pyrophosphate translocase, L 970871 is a reversible and competitive inhibitor of glucose-6-phosphate translocase.

The physico-chemical and spectral properties of L 970871 are summarized in Table 1.

Table 1

L 970871

Nature: Reddish brown solid Solubility: MeOH, DMSO and water Melting point: > 235° C (decomp.) D: - 344° (c 0.02, MeOH) HPLC RT: 1 1.90 min

Fig. 1 of the accompanying drawings

ESI-MS (Electrospray lonization: 527 (M-H)^~

Mass) Molecular formula: C28H-16O11 UV: Fig. 2 of the accompanying drawings

IR (KBr) cm^"1: Fig. 3 of the accompanying drawings

¹H NMR (300 MHz, DMSO-cfe): Fig. 4 of the accopmanying drawings ¹³C NMR (300 MHz, DMSO-cfe): Fig. 5 of the accompanying drawings 12

BUDA^PEST TREATY ON THE INTERNATIONAL

....COGNITION OF THE CEPO^r OF VICRCORCV NISMS

FOR THE PURPOSES Of PATENT PROCEDURE

INTERNATIONAL FORM

Hoechst Marion Roussel Deutschland GmbH

65926 Frankfurt/Main

RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT issued pursuant to Rule 7 1 by the

INTERNATIONAL DEPOSITARY AUTHORITY identified at the bottom of this page

I IDENTIFICATION OF THE MICROORGANISM

Identification reference given by the DEPOSITOR. Accession number given by die INTERNATIONAL DEPOSITARY AUTHORITY HIL 007997

DSM 11993

II. SCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION

The microorganism identified under I. above was accompanied by

( ) a scientific description

(X ) a proposed taxonomic designation

(Mark with a cross where applicable)

m RECEIPT AND ACCEPTANCE

This International Depositary Authoπty accepts the microorganism identified under I. above, which was received by it on 1998 - 0 2 - 10 (Date of the oπg al deposit)¹

IV RECBPT OF REQUEST FOR CONVERSION

The microorganism identified under I above was received by this Intemationai Depositary Authoπty on (date of oπgmal deposit) and a request to convert the oπgmal deposit to a deposit under the Budapest Treaty was received by it on (date of receipt of request for conversion).

V INTERNATIONAL DEPOSITARY AUTHORITY

Name DSMZ-DEUTSCHE SAMMLUNG VON Sιgnature(s) of person(s) having the power to represent die

MIKROORGANISMEN UND ZELLKULTUREN GmbH International Depositary Authority or of authorized offιcιal(s)

Address Mascheroder Weg lb

D S 124 Braunschweig

Date 1998 - 02 - 12

' Where Rule 6 4 (d) applies, buch date is the date on which the status ot international depositary authority was acquired Form DSMZ-BP/4 (sole page) 0196 13

BUDAPEST TREATY ON THF INTERNATIONAL ivcCOGNITION OF THE DfcPOSI T OF ICROCRG, f ISMS

FOR THE PURPOSES OF PA^-rENT PROCEDURE

INTERNATIONAL FORM

Hoechst Marion Roussel Deutschland GmbH

65926 Frankfurt/Mam

VIABILITY STATEMENT issued pursuant to Rule 102 by the INTERNATIONAL DEPOSITARY AUTHORITY identified at the bottom of this page

I DEPOSITOR π IDENTIFICATION OF THE MICROORGANISM

Name Hoechst Marxon Roussel Accession number given by the Deutschland GmbH INTERNATIONAL DEPOSITARY AUTHORITY

Address DSM 11993

65926 Frankfurt /Mam

Date of the deposit or the transfer' 1998 - 02 -10

πi VIABILITY STATEMENT

The viability of the microorganism identified under II above was tested on 1998 - 02 - 10 * On that date, the said microorganism was

(X)^J viable

( )^] no longer viable

IV CONDITIONS UNDER WHICH THE VIABILITY TEST HAS BEEN PERFORMED⁴

V INTERNATIONAL DEPOSITARY AUTHORITY

Name DSMZ-DEUTSCHE SAMMLUNG VON Sιgπature(s) of persoπ(s) having the power to represent the MIKROORGANISMEN UND ZELLKULTUREN GmbH International Depositary Authority or of authoπzed officιal(s)

Address Mascheroder Weg lb D-3S I24 Braunschweig

Date 1998 -02 - 12

Indicate the date ot oπgmal deposit or where a new deposit or a transfer has been made the most recent relevant date (date of the new deposit or date of the transfer)

In die cases referred to Rule 10 2(a) (u) and (in) refer to the most recent viability test

Vlark with a crobs the applicable box

Fill in it the information has been requested and if the results ot the test were negative

Form DSMZ BP/9 (sole page) 0196

Claims

14 Claims:

1. A compound of molecular formula C₂₈H₁₆O╬╣╬╣ (compound L 970871 ), obtainable from Actinomycete sp. HIL-007997 (DSM 11993) by fermenting Actinomycete sp. HIL-007997 in a culture medium until compound L 970871 accumulates in the culture broth, and subsequently isolating and purifying the active substance, and the pharmacologically acceptable salts thereof.

2. A chemical derivative derived from a compound of molecular formula C₂₈H₁₆On (compound L 970871 ), obtainable from Actinomycete sp. HIL-

007997 (DSM 11993) by fermenting Actinomycete sp. HIL-007997 in a culture medium until compound L 970871 accumulates in the culture broth, subsequently isolating and purifying the active substance and converting into chemical derivatives, and to the pharmacologically acceptable salts thereof.

3. A process for the preparation of a compound as claimed in one or more of claims 1-2, which comprises fermenting Actinomycete sp. HIL-007997 or its mutants and/or variants in a culture medium until compound L 970871 accumulates in the culture broth, and isolating the latter from the culture broth and optionally converting it into a chemical derivative.

4. The process as claimed in claim 3, wherein Actinomycete sp. HIL-007997 or its mutants and/or variants is fermented in a culture medium containing a carbon source, a nitrogen source and nutrient inorganic salts under aerobic conditions.

5. The process as claimed in one or more of claims 3-4, wherein the fermentation is carried out at a pH between 6 and 8 and at a temperature of 25-30┬░ C for 40-70 hours.

The process as claimed in one or more of claims 3-5, wherein the cultivation is carried out at a pH of 7 and at a temperature of 27┬░C ((+ 1┬░C). 15

7. The process as claimed in one or more of claims 3-6, wherein the cultivation is carried out for 60-70 hours under submerged conditions in shake flasks.

8. The process as claimed in one or more of claims 3-6, wherein the cultivation is carried out for 43-48 hours under submerged conditions in laboratory fermenters.

9. A compound as claimed in one or more of claims 1-2 for use as a medicament.

10. A pharmaceutical composition containing at least one compound as claimed in one or more of claims 1-2 and one or more physiologically acceptable excipients and, where appropriate, suitable additives and/or ancillary substances.

11. A process for the production of a pharmaceutical as claimed in claim 10, which comprises mixing at least one active compound as claimed in one or more of claims 1-2 with a physiologically acceptable excipient and, where appropriate, suitable additives and/or ancillary substances.

12. Use of a compound as claimed in one or more of claims 1 to 2 in the manufacture of a medicament for the treatment and/or prophylaxis of diabetes mellitus.

13. Actinomycete sp. HIL-007997 (DSM 1 1993).